172 related articles for article (PubMed ID: 12452758)
1. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis.
Salkind AR; Cuddy PG; Foxworth JW
Ann Pharmacother; 2002 Dec; 36(12):1938-43. PubMed ID: 12452758
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
3. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
[TBL] [Abstract][Full Text] [Related]
5. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
Vardakas KZ; Siempos II; Grammatikos A; Athanassa Z; Korbila IP; Falagas ME
CMAJ; 2008 Dec; 179(12):1269-77. PubMed ID: 19047608
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
7. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
[TBL] [Abstract][Full Text] [Related]
8. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
Zhang L; Wang R; Falagas ME; Chen LA; Liu YN
Chin Med J (Engl); 2012 Feb; 125(4):687-95. PubMed ID: 22490497
[TBL] [Abstract][Full Text] [Related]
9. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
Lee JH; Kim HJ; Kim YH
J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
[TBL] [Abstract][Full Text] [Related]
10. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia: A Multicenter Retrospective Cohort Study.
Bai AD; Srivastava S; Wong BKC; Digby GC; Razak F; Verma AA
Chest; 2024 Jan; 165(1):68-78. PubMed ID: 37574164
[TBL] [Abstract][Full Text] [Related]
12. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis.
Maimon N; Nopmaneejumruslers C; Marras TK
Eur Respir J; 2008 May; 31(5):1068-76. PubMed ID: 18216053
[TBL] [Abstract][Full Text] [Related]
14. Advances in antibiotic therapy for community-acquired pneumonia.
Viasus D; Garcia-Vidal C; Carratalà J
Curr Opin Pulm Med; 2013 May; 19(3):209-15. PubMed ID: 23422416
[TBL] [Abstract][Full Text] [Related]
15. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis.
Xu LY; Wang CC; Peng XX; Jiao Y; Zhao CZ; Zhang L; Ma L
J Glob Antimicrob Resist; 2022 Sep; 30():1-9. PubMed ID: 35643393
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
Lee JS; Giesler DL; Gellad WF; Fine MJ
JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
[TBL] [Abstract][Full Text] [Related]
17. Sparfloxacin: a review.
Schentag JJ
Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
19. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
20. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
